Literature DB >> 11559549

Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells.

V Syed1, G Ulinski, S C Mok, G K Yiu, S M Ho.   

Abstract

Epidemiological data have implicated reproductive hormones as probable risk factors for ovarian cancer (OCa) development. Although pituitary and sex hormones have been reported to regulate OCa cell growth, no information is available regarding whether and how they influence normal ovarian surface epithelial (OSE) cell proliferation. To fill this data gap, this study has compared cell growth responses to gonadotropins and sex steroids in primary cultures of human OSE (HOSE) cells with those observed in immortalized, nontumorigenic HOSE cells and in OCa cell lines. Both malignant and normal cell lines/cultures responded equally well to the stimulatory actions of luteinizing hormone and follicle-stimulating hormone and to 17beta-estradiol and estrone, although the latter estrogen has a much lower affinity for estrogen receptor than does the former estrogen. In normal HOSE cell cultures/lines, 5alpha-dihydrotestosterone was found to be more effective than testosterone in stimulating cell growth, but in OCa cell lines, 5alpha-dihydrotestosterone and testosterone are equally potent. One OCa cell line, OVCA 433, was found to be nonresponsive to androgen stimulation. In general, primary cultures of normal HOSE cells exhibited the greatest hormone-stimulated growth responses (>10-fold enhancement), followed by immortalized HOSE cell lines (4-5-fold enhancement) and by OCa cell lines (2-4-fold enhancement). Interestingly, progesterone (P4), at low concentrations (10(-11) to 10(-10) M), was stimulatory to HOSE and OCa cell growth, but at high doses (10(-8) to 10(-6) M), P4 exerted marked inhibitory effects. In all cases, cotreatment of a cell culture/line with a hormone and its specific antagonist blocked the effect of the hormone, confirming specificity of the hormonal action. Taken together, these data support the hypothesis that reproductive states associated with rising levels of gonadotropins, estrogen, and/or androgen promote cell proliferation in the normal OSE, which favors neoplastic transformation. Conversely, those states attended by high levels of circulating P4, such as that seen during pregnancy, induce OSE cell loss and offer protection against ovarian carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559549

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Dynamics of the primate ovarian surface epithelium during the ovulatory menstrual cycle.

Authors:  Jay W Wright; Leigh Jurevic; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

2.  Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.

Authors:  Jonathan Beesley; Susan J Jordan; Amanda B Spurdle; Honglin Song; Susan J Ramus; Suzanne Kruger Kjaer; Estrid Hogdall; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

3.  Hormone therapy and ovarian cancer: incidence and survival.

Authors:  Karen J Wernli; Polly A Newcomb; John M Hampton; Amy Trentham-Dietz; Kathleen M Egan
Journal:  Cancer Causes Control       Date:  2008-02-09       Impact factor: 2.506

4.  Hormesis [biological effects of low level exposures (BELLE)] and dermatology.

Authors:  Haw-Yueh Thong; Howard I Maibach
Journal:  Dose Response       Date:  2008-02-01       Impact factor: 2.658

5.  In vitro regulation of sheep ovarian surface epithelium (OSE) proliferation by local ovarian factors.

Authors:  Salina Yahya Saddick
Journal:  Saudi J Biol Sci       Date:  2012-03-30       Impact factor: 4.219

6.  Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Louise A Brinton; Garnet L Anderson; Ruth M Pfeiffer; Roni T Falk; Howard D Strickler; Sarunas Sliesoraitis; Lewis H Kuller; Margery L Gass; Barbara J Fuhrman; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-05       Impact factor: 4.254

Review 7.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

8.  miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.

Authors:  Yulei Wei; Hong Li; Quanxin Qu
Journal:  Breast Cancer       Date:  2020-08-31       Impact factor: 4.239

9.  Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk.

Authors:  Meghan A McSorley; Anthony J Alberg; Diane S Allen; Naomi E Allen; Louise A Brinton; Joanne F Dorgan; Rudolf Kaaks; Sabina Rinaldi; Kathy J Helzlsouer
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

10.  Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens.

Authors:  Sergio Eduardo Perniconi; Manuel de Jesus Simões; Ricardo Dos Santos Simões; Mauro Abi Haidar; Edmund C Baracat; Jose Maria Soares
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.